Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

Bihua Han(Hebei Provincial Center for Disease Control and Prevention), Yufei Song(Sinovac Biotech), Changgui Li(National Institutes for Food and Drug Control), Wanqi Yang(Sinovac Biotech), Qingxia Ma(Hebei Provincial Center for Disease Control and Prevention), Zhiwei Jiang, Minjie Li(Hebei Provincial Center for Disease Control and Prevention), Xiaojuan Lian, Wenbin Jiao(Hebei Provincial Center for Disease Control and Prevention), Lei Wang(Sinovac Biotech), Qun Shu, Zhiwei Wu(Hebei Provincial Center for Disease Control and Prevention), Yuliang Zhao(Hebei Provincial Center for Disease Control and Prevention), Qi Li(Hebei Provincial Center for Disease Control and Prevention), Qiang Gao
The Lancet Infectious Diseases
June 28, 2021
Cited by 355Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis